KP
Kwality Pharmaceuticals Ltd (KPL)
₹3,644.20
Mkt cap
₹3,602 Cr
P/E ratio
44.10
P/B
11.39
Div yield
0.00%
ROE
22.60%
ROCE
24.10%
EPS (TTM)
₹82.63
Book value
₹320
52W range
1,561–3,949
Sector
Healthcare
Price history
Previous close
Incorporated in 1983, Kwality Pharma is in the business of manufacturing & trading in Pharmaceuticals & allied products [1]
NSE KPLBSE 539997
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−7.72% from high₹3,644
₹1,561+133.45% from low₹3,949
Current
₹3,644.20
Prev close
₹3,564.40
Day
+2.24%
Price performance
1D
+1.98%
1W
−1.02%
1M
+7.22%
3M
+37.05%
6M
—
1Y
—
YTD
+119.19%
Financials
Revenue, profit & margin
P/E ratio
44.1×
KPL is 28% above the sector median of 34.6×
KPL44.1×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 67 | 70 | 78 | 92 | 80 | 90 | 84 | 116 | 111 | 111 | 123 | 157 | 162 | |
| Expenses | 54 | 54 | 61 | 71 | 63 | 70 | 67 | 90 | 87 | 86 | 93 | 118 | 121 | |
| Operating Profit | 14 | 15 | 17 | 21 | 17 | 20 | 18 | 26 | 24 | 25 | 30 | 39 | 41 | |
| OPM % | 20% | 22% | 21% | 22% | 22% | 22% | 21% | 22% | 22% | 23% | 24% | 25% | 25% | |
| Other Income | 0 | 0 | 1 | -7 | 0 | 0 | 1 | 1 | 0 | 1 | -0 | 1 | 1 | |
| Interest | 2 | 2 | 3 | 3 | 2 | 3 | 2 | 2 | 3 | 3 | 2 | 3 | 3 | |
| Depreciation | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | |
| Profit before tax | 7 | 8 | 10 | 6 | 11 | 13 | 11 | 19 | 17 | 18 | 22 | 32 | 34 | |
| Tax % | 25% | 24% | 21% | 29% | 25% | 33% | 25% | 24% | 30% | 23% | 28% | 20% | 25% | |
| Net Profit | 5 | 6 | 8 | 4 | 8 | 8 | 9 | 14 | 12 | 14 | 16 | 25 | 26 | |
| EPS in Rs | 5.22 | 6.01 | 7.41 | 4.20 | 8.06 | 8.16 | 8.22 | 13.96 | 11.50 | 13.61 | 15.43 | 24.38 | 24.69 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202654.86%Promoter
Promoters54.86%
FIIs3.13%0.34
DIIs0.56%0.20
Public41.45%0.54
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Kwality Pharma | ₹3,471.20 | 44.12 | 3,602 | 0.00% | 26 | +114.75% | 162 | +45.63% | 24.08% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports11
Concall transcripts14
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Change in Management 2 Sep - AGM approved Swanith Kapoor as independent director and Aditya Arora’s 5-year reappointment30 Sept 2026.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 2 SepShareholder Meeting / Postal Ballot-Outcome of AGM 31 Aug - Kwality Pharmaceuticals held its 43rd AGM on August 31, 2026, approving six resolutions including director reappointments.Announcement under Regulation 30 (LODR)-Newspaper Publication 13 Aug - Newspaper Publication of Unaudited Financial Results for the quarter ended June 30, 2026.Announcement under Regulation 30 (LODR)-Newspaper Publication 12 Aug - Newspaper Publication of Notice of 43rd Annual General Meeting.